Antifibrotics Up Outcomes After Ahmed Glaucoma Valve Implant

This article originally appeared here.
Share this content:
Antifibrotics Up Outcomes After Ahmed Glaucoma Valve Implant
Antifibrotics Up Outcomes After Ahmed Glaucoma Valve Implant

WEDNESDAY, Aug. 10, 2016 (HealthDay News) -- Mitomycin C (MMC) and 5-flurouracil (5-FU) improve outcomes following Ahmed glaucoma valve (AGV) implantation, according to a study published online Aug. 4 in Clinical & Experimental Ophthalmology.

Qi N. Cui, M.D., Ph.D., from the University of California in San Francisco, and colleagues examined the effect of MMC and 5-FU on treatment outcomes for 50 patients who received AGV implantation. Patients received intraoperative MMC followed by postoperative injections of MMC and/or 5-FU (+INJECTION) group (26 patients/eyes) or not (−INJECTION; 24 patients/eyes).

The researchers observed higher treatment success in the +INJECTION group versus the −INJECTION group (86 versus 58 percent; P = 0.04). At one, three, six, and 12 months, intraocular pressure was lower in the +INJECTION group versus the −INJECTION group. In the +INJECTION group, hypertensive phase (HP) occurred less often (3.8 percent, compared to 54 percent in the −INJECTION group; P = 0.021). At one, three, six, and 12 months, fewer medications were required by the +INJECTION group. Comparable complication rates were seen between the +INJECTION and −INJECTION groups (46.2 and 54.2 percent, respectively; P = 0.63).

"Adjuvant treatment with antifibrotics following AGV implantation decreased the HP and improved surgical outcomes without impacting complication rates at one year," the authors write. "This study postulates a role for antifibrotics in the postoperative management of AGV implantation."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »